Akorn recalls Levofloxacin eye drops due to manufacturing compliance issues
Akorn, Inc. is recalling Levofloxacin Ophthalmic Solution due to manufacturing process deviations. The voluntary recall affects 3,108 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Voluntary, precautionary FDA Class II recall for manufacturing process deviations with no reported illnesses or injuries. The absence of demonstrated harm and precautionary nature classify this as Moderate severity.
Plain-English summary
Akorn, Inc. is recalling Levofloxacin Ophthalmic Solution 0.5%, 5 mL bottles. The product is a prescription eye medication (NDC 17478-106-10).
The recall is due to current good manufacturing practice (CGMP) deviations identified in the manufacturing process. This is a voluntary, precautionary recall initiated by the manufacturer.
The affected product was lot #1F43A, expiring 5/31/2023, and was distributed nationwide in the United States. Approximately 3,108 bottles are affected.
Patients currently using this medication should consult their healthcare provider before stopping treatment or switching to an alternative. Healthcare providers should verify whether their supply includes affected lot numbers.
The recalled product
- Product
- Levofloxacin Ophthalmic Solution 0.5%, 5 mL per bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, Il 60045. NDC: 17478-106-10
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic / Eye Drops
- Hazard
- Affected units
- 3,108
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 1F43A
- EXP 5/31/2/023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09